US20090088470A1 - Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics - Google Patents
Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics Download PDFInfo
- Publication number
- US20090088470A1 US20090088470A1 US12/328,386 US32838608A US2009088470A1 US 20090088470 A1 US20090088470 A1 US 20090088470A1 US 32838608 A US32838608 A US 32838608A US 2009088470 A1 US2009088470 A1 US 2009088470A1
- Authority
- US
- United States
- Prior art keywords
- alkyl group
- hydrogen atom
- disease
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 title description 8
- 125000000217 alkyl group Chemical group 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 31
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 10
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 8
- 230000007170 pathology Effects 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 230000000926 neurological effect Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010063897 Renal ischaemia Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 230000006399 behavior Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims description 2
- 208000010118 dystonia Diseases 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 208000018198 spasticity Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- -1 heptenyl Chemical group 0.000 description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 44
- 239000011734 sodium Substances 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 0 [1*]N([2*])C(=O)OC([3*])C(=O)N([4*])[H] Chemical compound [1*]N([2*])C(=O)OC([3*])C(=O)N([4*])[H] 0.000 description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- UWSAJFLHCORFBP-PLNGDYQASA-N [2-(methylamino)-2-oxoethyl]-[(Z)-tetradec-11-enyl]carbamic acid Chemical compound CC\C=C/CCCCCCCCCCN(C(O)=O)CC(=O)NC UWSAJFLHCORFBP-PLNGDYQASA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- DJMKPRPHMQRSGE-ARJAWSKDSA-N (2-amino-2-oxoethyl)-[(Z)-tetradec-11-enyl]carbamic acid Chemical compound CC\C=C/CCCCCCCCCCN(C(O)=O)CC(N)=O DJMKPRPHMQRSGE-ARJAWSKDSA-N 0.000 description 3
- SXKLTNVBZLFVSL-ARJAWSKDSA-N 3-[(z)-tetradec-11-enyl]-1,3-oxazolidine-2,4-dione Chemical compound CC\C=C/CCCCCCCCCCN1C(=O)COC1=O SXKLTNVBZLFVSL-ARJAWSKDSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 201000002661 Spondylitis Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000006165 cyclic alkyl group Chemical group 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UDERUZYGCOSKFS-FPLPWBNLSA-N (2-amino-2-oxoethyl)-[(Z)-hexadec-9-enyl]carbamic acid Chemical compound CCCCCC\C=C/CCCCCCCCN(C(O)=O)CC(N)=O UDERUZYGCOSKFS-FPLPWBNLSA-N 0.000 description 2
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- PKHJVTPXTHAEDU-ZDVGBALWSA-N [(11E,14E)-icosa-11,14-dienyl]-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCCN(C(O)=O)CC(=O)NC PKHJVTPXTHAEDU-ZDVGBALWSA-N 0.000 description 2
- OVWVDKHTSAUTHS-JSIPCRQOSA-N [(11E,14E,17E)-icosa-11,14,17-trienyl]-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CC\C=C\C\C=C\C\C=C\CCCCCCCCCCN(C(O)=O)CC(=O)NC OVWVDKHTSAUTHS-JSIPCRQOSA-N 0.000 description 2
- XMTZRRBNVNLASY-ZKWNWVNESA-N [(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenyl]-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCN(C(O)=O)CC(=O)NC XMTZRRBNVNLASY-ZKWNWVNESA-N 0.000 description 2
- ADRLUSSDOAGPGI-HJWRWDBZSA-N [(Z)-hexadec-9-enyl]-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CCCCCC\C=C/CCCCCCCCN(C(O)=O)CC(=O)NC ADRLUSSDOAGPGI-HJWRWDBZSA-N 0.000 description 2
- PVNHVLPLQMBNSK-SPOHZTNBSA-N [2-(methylamino)-2-oxoethyl]-[(6E,9E,12E)-octadeca-6,9,12-trienyl]carbamic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\CCCCCN(C(O)=O)CC(=O)NC PVNHVLPLQMBNSK-SPOHZTNBSA-N 0.000 description 2
- FAEJNEFAGHSVJN-YPKPFQOOSA-N [2-(methylamino)-2-oxoethyl]-[(Z)-octadec-6-enyl]carbamic acid Chemical compound CCCCCCCCCCC\C=C/CCCCCN(C(O)=O)CC(=O)NC FAEJNEFAGHSVJN-YPKPFQOOSA-N 0.000 description 2
- HOAKYOVTTHTXJB-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl]-nonadecylcarbamic acid Chemical compound CCCCCCCCCCCCCCCCCCCN(C(O)=O)CC(=O)NC HOAKYOVTTHTXJB-UHFFFAOYSA-N 0.000 description 2
- LYADKOFXHNMGBS-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl]-pentadecylcarbamic acid Chemical compound CCCCCCCCCCCCCCCN(C(O)=O)CC(=O)NC LYADKOFXHNMGBS-UHFFFAOYSA-N 0.000 description 2
- GCDSORHSCKYLHQ-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl]-tetradecan-2-ylcarbamic acid Chemical compound CCCCCCCCCCCCC(C)N(C(O)=O)CC(=O)NC GCDSORHSCKYLHQ-UHFFFAOYSA-N 0.000 description 2
- QAMUQURLMQYHOR-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl]-tetradecylcarbamic acid Chemical compound CCCCCCCCCCCCCCN(C(O)=O)CC(=O)NC QAMUQURLMQYHOR-UHFFFAOYSA-N 0.000 description 2
- LCECKEIXSOGBCF-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl]-undecan-2-ylcarbamic acid Chemical compound CCCCCCCCCC(C)N(C(O)=O)CC(=O)NC LCECKEIXSOGBCF-UHFFFAOYSA-N 0.000 description 2
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- XOLSBECFCBZFDE-UHFFFAOYSA-N cyclododecyl-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CNC(=O)CN(C(O)=O)C1CCCCCCCCCCC1 XOLSBECFCBZFDE-UHFFFAOYSA-N 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- HYYFUDFYVIUPKX-UHFFFAOYSA-N decyl-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CCCCCCCCCCN(C(O)=O)CC(=O)NC HYYFUDFYVIUPKX-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- OWBRDPGFGHYKAM-UHFFFAOYSA-N dodecyl-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CCCCCCCCCCCCN(C(O)=O)CC(=O)NC OWBRDPGFGHYKAM-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005064 octadecenyl group Chemical group C(=CCCCCCCCCCCCCCCCC)* 0.000 description 2
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 description 2
- 150000001475 oxazolidinediones Chemical class 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000005063 tetradecenyl group Chemical group C(=CCCCCCCCCCCCC)* 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000005490 tosylate group Chemical group 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- IZYSNLQGZSXJFM-UHFFFAOYSA-N (1-amino-1-oxopropan-2-yl)-decylcarbamic acid Chemical compound CCCCCCCCCCN(C(O)=O)C(C)C(N)=O IZYSNLQGZSXJFM-UHFFFAOYSA-N 0.000 description 1
- STUGAISSEDESND-UHFFFAOYSA-N (1-amino-1-oxopropan-2-yl)-hexylcarbamic acid Chemical compound CCCCCCN(C(O)=O)C(C)C(N)=O STUGAISSEDESND-UHFFFAOYSA-N 0.000 description 1
- UMISPHIWIJYMAZ-UHFFFAOYSA-N (1-amino-1-oxopropan-2-yl)-octylcarbamic acid Chemical compound CCCCCCCCN(C(O)=O)C(C)C(N)=O UMISPHIWIJYMAZ-UHFFFAOYSA-N 0.000 description 1
- DBFRFIBKHYTNAZ-UHFFFAOYSA-N (1-amino-1-oxopropan-2-yl)-pentylcarbamic acid Chemical compound CCCCCN(C(O)=O)C(C)C(N)=O DBFRFIBKHYTNAZ-UHFFFAOYSA-N 0.000 description 1
- GXBIVYIAPRBFJV-DOFZRALJSA-N (2-amino-2-oxoethyl)-[(4Z,7Z,10Z,13Z)-nonadeca-4,7,10,13-tetraenyl]carbamic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCN(C(O)=O)CC(N)=O GXBIVYIAPRBFJV-DOFZRALJSA-N 0.000 description 1
- KVRRHZWTMDZCNY-SNAWJCMRSA-N (2-amino-2-oxoethyl)-[(E)-hex-2-enyl]carbamic acid Chemical compound CCC\C=C\CN(C(O)=O)CC(N)=O KVRRHZWTMDZCNY-SNAWJCMRSA-N 0.000 description 1
- ACYGXVOTAMYRPM-ONEGZZNKSA-N (2-amino-2-oxoethyl)-[(E)-hex-3-enyl]carbamic acid Chemical compound CC\C=C\CCN(C(O)=O)CC(N)=O ACYGXVOTAMYRPM-ONEGZZNKSA-N 0.000 description 1
- URTLHUNHDGIKTN-VOTSOKGWSA-N (2-amino-2-oxoethyl)-[(E)-oct-2-enyl]carbamic acid Chemical compound CCCCC\C=C\CN(C(O)=O)CC(N)=O URTLHUNHDGIKTN-VOTSOKGWSA-N 0.000 description 1
- KVRRHZWTMDZCNY-PLNGDYQASA-N (2-amino-2-oxoethyl)-[(Z)-hex-2-enyl]carbamic acid Chemical compound CCC\C=C/CN(C(O)=O)CC(N)=O KVRRHZWTMDZCNY-PLNGDYQASA-N 0.000 description 1
- ACYGXVOTAMYRPM-ARJAWSKDSA-N (2-amino-2-oxoethyl)-[(Z)-hex-3-enyl]carbamic acid Chemical compound CC\C=C/CCN(C(O)=O)CC(N)=O ACYGXVOTAMYRPM-ARJAWSKDSA-N 0.000 description 1
- BRXJDGLHEAURGW-WAYWQWQTSA-N (2-amino-2-oxoethyl)-[(Z)-oct-3-enyl]carbamic acid Chemical compound CCCC/C=C\CCN(CC(=O)N)C(=O)O BRXJDGLHEAURGW-WAYWQWQTSA-N 0.000 description 1
- FFFQYYGCPDWBTF-ARJAWSKDSA-N (2-amino-2-oxoethyl)-[(Z)-oct-5-enyl]carbamic acid Chemical compound CC\C=C/CCCCN(C(O)=O)CC(N)=O FFFQYYGCPDWBTF-ARJAWSKDSA-N 0.000 description 1
- CPLLGFKBBBISJB-SEYXRHQNSA-N (2-amino-2-oxoethyl)-[(Z)-octadec-6-enyl]carbamic acid Chemical compound CCCCCCCCCCC\C=C/CCCCCN(C(O)=O)CC(N)=O CPLLGFKBBBISJB-SEYXRHQNSA-N 0.000 description 1
- UCCGUYJBAIYYRB-UHFFFAOYSA-N (2-amino-2-oxoethyl)-oct-7-enylcarbamic acid Chemical compound NC(=O)CN(C(O)=O)CCCCCCC=C UCCGUYJBAIYYRB-UHFFFAOYSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- YGHAIPJLMYTNAI-ARJAWSKDSA-N (z)-tetradec-11-en-1-ol Chemical compound CC\C=C/CCCCCCCCCCO YGHAIPJLMYTNAI-ARJAWSKDSA-N 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 238000011795 OF1 mouse Methods 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- UYXHLPWIEHFKHB-AATRIKPKSA-N [(E)-hex-2-enyl]-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CCC\C=C\CN(C(O)=O)CC(=O)NC UYXHLPWIEHFKHB-AATRIKPKSA-N 0.000 description 1
- GTIPKDWMLCWTMO-SNAWJCMRSA-N [(E)-hex-3-enyl]-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CC\C=C\CCN(C(O)=O)CC(=O)NC GTIPKDWMLCWTMO-SNAWJCMRSA-N 0.000 description 1
- YSBCLRDLCFHRIQ-ZHACJKMWSA-N [(E)-icos-11-enyl]-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CCCCCCCC\C=C\CCCCCCCCCCN(C(O)=O)CC(=O)NC YSBCLRDLCFHRIQ-ZHACJKMWSA-N 0.000 description 1
- UYXHLPWIEHFKHB-WAYWQWQTSA-N [(Z)-hex-2-enyl]-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CCC\C=C/CN(C(O)=O)CC(=O)NC UYXHLPWIEHFKHB-WAYWQWQTSA-N 0.000 description 1
- GTIPKDWMLCWTMO-PLNGDYQASA-N [(Z)-hex-3-enyl]-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CC\C=C/CCN(C(O)=O)CC(=O)NC GTIPKDWMLCWTMO-PLNGDYQASA-N 0.000 description 1
- YLLSBMHBSWNXSN-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl] n-decylcarbamate Chemical compound CCCCCCCCCCNC(=O)OCC(=O)NC YLLSBMHBSWNXSN-UHFFFAOYSA-N 0.000 description 1
- RYJWTHIBHAHLQI-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl] phenyl carbonate Chemical compound CNC(=O)COC(=O)OC1=CC=CC=C1 RYJWTHIBHAHLQI-UHFFFAOYSA-N 0.000 description 1
- CDJFZFFIKQUFBX-BQYQJAHWSA-N [2-(methylamino)-2-oxoethyl]-[(E)-oct-2-enyl]carbamic acid Chemical compound CCCCC\C=C\CN(C(O)=O)CC(=O)NC CDJFZFFIKQUFBX-BQYQJAHWSA-N 0.000 description 1
- JSHDQGTZHRWSQY-SREVYHEPSA-N [2-(methylamino)-2-oxoethyl]-[(Z)-oct-3-enyl]carbamic acid Chemical compound CCCC\C=C/CCN(C(O)=O)CC(=O)NC JSHDQGTZHRWSQY-SREVYHEPSA-N 0.000 description 1
- QBTKKSWGMULNKD-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl]-nonylcarbamic acid Chemical compound CCCCCCCCCN(C(O)=O)CC(=O)NC QBTKKSWGMULNKD-UHFFFAOYSA-N 0.000 description 1
- QVMGORNWLBFZCY-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl]-oct-7-enylcarbamic acid Chemical compound CNC(=O)CN(C(O)=O)CCCCCCC=C QVMGORNWLBFZCY-UHFFFAOYSA-N 0.000 description 1
- MUYSLMHMXQCTNU-UHFFFAOYSA-N [2-(methylamino)-2-oxoethyl]-octan-2-ylcarbamic acid Chemical compound CCCCCCC(C)N(C(O)=O)CC(=O)NC MUYSLMHMXQCTNU-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000013355 benign neoplasm of brain Diseases 0.000 description 1
- 206010004398 benign neoplasm of skin Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XQEXFOFYKOXMLB-UHFFFAOYSA-N cyclooctyl-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CNC(=O)CN(C(O)=O)C1CCCCCCC1 XQEXFOFYKOXMLB-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DBORMMGHOSIZMC-UHFFFAOYSA-N heptyl-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CCCCCCCN(C(O)=O)CC(=O)NC DBORMMGHOSIZMC-UHFFFAOYSA-N 0.000 description 1
- YGUISXRWSKNZKI-UHFFFAOYSA-N hexyl-[2-(methylamino)-2-oxoethyl]carbamic acid Chemical compound CCCCCCN(C(O)=O)CC(=O)NC YGUISXRWSKNZKI-UHFFFAOYSA-N 0.000 description 1
- GAZPWIYUMKXVBS-UHFFFAOYSA-N hexyl-[8-(methylamino)-8-oxooctyl]carbamic acid Chemical compound CCCCCCN(C(O)=O)CCCCCCCC(=O)NC GAZPWIYUMKXVBS-UHFFFAOYSA-N 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 208000029986 neuroepithelioma Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 1
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003774 sarcomatosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 11/874,959, filed Oct. 19, 2007, now allowed, which is a continuation of International application No. PCT/FR2006/000,958, filed Apr. 28, 2006, both of which are incorporated herein by reference in their entirety; which claims the benefit of priority of French Patent Application No. 05/04,492, filed May 3, 2005.
- The invention relates to alkyl-, alkenyl- and alkynylcarbamate derivatives, to their preparation and to their application in therapeutics.
- The compounds of the invention correspond to the general formula (I)
- in which
R1, represents a C5-26-alkyl, C5-26-alkenyl or C5-26-alkynyl group or a polyunsaturated aliphatic carbon group comprising between 5 and 26 carbon atoms and comprising at least two unsaturations chosen from double and triple bonds;
R2 represents a hydrogen atom or a C1-6-alkyl group;
R3 represents a hydrogen atom or a C1-3-alkyl;
R4 represents a hydrogen atom or a C1-4-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkyl group. - The compounds of general formula (I) can comprise one or more asymmetric carbons. They can exist in the form of enantiomers or of diastereoisomers. The compounds of general formula (I) can also exist in the form of cis or trans stereoisomers. These enantiomers, diastereoisomers and stereoisomers, and their mixtures, including racemic mixtures, form part of the invention.
- The compounds of general formula (I) can exist in the form of hydrates or of solvates, namely in the form of combinations or associations with one or more molecules of water or with a solvent. Such hydrates and solvates also form part of the invention.
- In the context of the present invention:
-
- Ct-z where t and z can take the values from 1 to 26 is understood to mean a carbon chain which can have from t to z carbon atoms, for example C1-3 a carbon chain which can have from 1 to 3 carbon atoms;
- an alkyl group is understood to mean: a saturated, linear, branched or cyclic aliphatic group; for example a C1-3-alkyl group represents a carbon chain which can have from 1 to 3 carbon atoms, for example a methyl, ethyl, propyl, isopropyl, cyclopropyl, and the like;
- an alkenyl group is understood to mean: a linear, branched or cyclic alkyl group comprising a double bond, for example a C5-26-alkenyl group represents a linear, branched or cyclic carbon chain of 5 to 26 carbon atoms comprising a double bond, for example a pentenyl, cyclopentenyl, hexenyl, cyclohexenyl, heptenyl, cycloheptenyl, octenyl, cyclooctenyl, and the like;
- an alkynyl group is understood to mean: a linear, branched or cyclic alkyl group comprising a triple bond, for example a C5-26-alkynyl group represents a linear, branched or cyclic carbon chain of 5 to 26 carbon atoms comprising a triple bond, for example a hexynyl, heptynyl, octynyl, and the like;
- a polyunsaturated aliphatic carbon group is understood to mean: a linear, branched or cyclic alkyl group comprising at least two unsaturations chosen from double and triple bonds, for example a pentadienyl, hexadienyl, cyclohexadienyl, heptadienyl, heptatrienyl, cycloheptadienyl, cycloheptatrienyl, pentadiynyl, hexadiynyl or heptadiynyl.
- Among the compounds of general formula (I) which are subject-matters of the invention, a first group of compounds is composed of the compounds for which:
-
- R1 represents
a C5-26-alkyl group, more particularly a pentyl, hexyl, heptyl, octyl, cyclooctyl, 1-methylheptyl, nonyl, decyl, 1-methyldecyl, dodecyl, cyclododecyl, tetradecyl, 1-methyltridecyl, pentadecyl, octadecyl or nonadecyl; a C5-26-alkenyl group, more particularly a hexenyl, octenyl, tetradecenyl, hexadecenyl, octadecenyl or icosenyl group; or a polyunsaturated aliphatic carbon group comprising between 5 and 26 carbon atoms and comprising at least two unsaturations chosen from double bonds, more particularly an octadecatrienyl, nonadecatetraenyl, icosadienyl, icosatrienyl or icosatetraenyl; - and/or R2 represents a hydrogen atom or a C1-6-alkyl group, more particularly a methyl or a hexyl;
- and/or R3 represents a hydrogen atom or a C1-3-alkyl group;
- and/or R4 represents a hydrogen atom or a C1-4-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkyl group.
- R1 represents
- Mention may be made, among the compounds of this first group, of the compounds of formula (I) for which:
- R3 represents a hydrogen atom or a C1-3-alkyl group, more particularly a methyl;
and/or R4 represents a hydrogen atom or a C1-4-alkyl group, more particularly a methyl. - Mention may in particular be made, among the compounds of this first group, of the following compounds:
- 2-Amino-1-methyl-2-oxoethyl(pent-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((2E)-hex-2-en-1-yl)carbamate
- 2-Amino-2-oxoethyl((2E)-hex-2-en-1-yl)carbamate
- 2-Amino-2-oxoethyl((2Z)-hex-2-en-1-yl)carbamate
- 2-Amino-2-oxoethyl((3Z)-hex-3-en-1-yl)carbamate
- 2-Amino-2-oxoethyl((3E)-hex-3-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((3Z)-hex-3-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((3E)-hex-3-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((2Z)-hex-2-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(hex-1-yl)carbamate
- 2-Amino-1-methyl-2-oxoethyl(hex-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(dihex-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(hept-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((2E)-oct-2-en-1-yl)carbamate
- 2-Amino-2-oxoethyl((2E)-oct-2-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((3Z)-oct-3-en-1-yl)carbamate
- 2-Amino-2-oxoethyl((3Z)-oct-3-en-1-yl)carbamate
- 2-Amino-2-oxoethyl((5Z)-oct-5-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((5Z)-oct-5-en-1
- yl)carbamate
- 2-Amino-2-oxoethyl(oct-7-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(oct-7-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(cyclooct-1-yl)carbamate
- 2-Amino-1-methyl-2-oxoethyl(oct-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(1-methylhept-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(non-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(dec-1-yl)carbamate
- 2-Amino-1-methyl-2-oxoethyl(dec-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(1-methyldec-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(cyclododec-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(dodec-1-yl)carbamate
- 2-Amino-2-oxoethyl((11Z)-tetradec-11-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((11Z)-tetradec-11-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(tetradec-1-yl)carbamate
- 2-Amino-2-oxoethyl((9Z)-hexadec-9-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((9Z)-hexadec-9-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(1-methyltridecyl)carbamate
- 2-(Methylamino)-2-oxoethyl(pentadec-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((6E,9E,12E)-octadeca-6,9,12-trien-1-yl)carbamate
- 2-Amino-2-oxoethyl((6Z)-octadec-6-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((6Z)-octadec-6-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((methyl)octadec-1-yl)carbamate
- 2-Amino-2-oxoethyl((4Z,7Z,10Z,13Z)-nonadeca-4,7,10,13-tetraen-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(nonadec-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((11E,14E,17E)-icosa-11,14,17-trien-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((11E,14E)-icosa-11,14-dien-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((11E)-icosa-11-en-1-yl)carbamate.
- Among the compounds of general formula (I) which are subject-matters of the invention, a second group of compounds is composed of the compounds for which:
-
- R1 represents a C10-20-alkyl, C10-20-alkenyl or C10-20-alkynyl group or a polyunsaturated aliphatic carbon group comprising between 10 and 20 carbon atoms and comprising at least two unsaturations chosen from double and triple bonds;
- and/or R2 represents a hydrogen atom or a C1-6-alkyl group, more particularly a methyl or a hexyl;
- and/or R3 represents a hydrogen atom or a C1-3-alkyl group;
- and/or R4 represents a hydrogen atom or a C1-4-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkyl group.
- Mention may be made, among the compounds of this second group, of the compounds of formula (I) for which:
-
- R1 represents a C10-20-alkyl group, more particularly a decyl, methyldecyl, dodecyl, cyclododecyl, methyltridecyl, tetradecyl, pentadecyl, octadecyl or nonadecyl, a C10-20-alkenyl group, more particularly a tetradecenyl, hexadecenyl, octadecenyl or icosenyl, or a polyunsaturated aliphatic carbon group comprising between 10 and 20 carbon atoms and comprising at least two unsaturations chosen from double bonds, more particularly an octadecatrienyl, nonadecatetraenyl, icosadienyl, icosatrienyl or icosatetraenyl;
- and/or R2 represents a hydrogen atom or a C1-6-alkyl group, more particularly a methyl;
- and/or R3 represents a hydrogen atom or a C1-3-alkyl group, more particularly a methyl;
- and/or R4 represents a hydrogen atom or a C1-4-alkyl group, more particularly a methyl.
- The following compounds may be mentioned among the compounds of the subgroup defined above:
- 2-(Methylamino)-2-oxoethyl(dec-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(1-methyldec-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(cyclododec-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(dodec-1-yl)carbamate
- 2-Amino-2-oxoethyl((11Z)-tetradec-11-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((11Z)-tetradec-11-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(tetradec-1-yl)carbamate
- 2-Amino-2-oxoethyl((9Z)-hexadec-9-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((9Z)-hexadec-9-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl(1-methyltridecyl)carbamate
- 2-(Methylamino)-2-oxoethyl(pentadec-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((6E,9E,12E)-octadeca-6,9,12-trien-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((6Z)-octadec-6-en-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((11E,14E,17E)-icosa-11,14,17-trien-1-yl)carbamate
- 2-(Methylamino)-2-oxoethyl((11E,14E)-icosa-11,14-dien-1-yl)carbamate.
- The compounds of the invention can be prepared according to various methods illustrated by the schemes which follow.
- Thus, according to a first method (Scheme 1), the compounds of general formula (I) can be prepared by reacting an amine of general formula (II), in which R1 and R2 are as defined in the general formula (I), with a carbonate of general formula (III), in which Z represents a hydrogen atom or a nitro group while R3 and R4 are as defined in the general formula (I).
- The carbonates of general formula (III) can be prepared according to any method described in the literature, for example by reaction of an alcohol of general formula HOCHR3CONHR4, where R3 and R4 are as defined in the general formula (I), with phenyl or 4-nitrophenyl chloroformate in the presence of a base, such as triethylamine or diisopropylethylamine.
- Another method (Scheme 2) for obtaining compounds of general formula (I) in which R2 represents a hydrogen atom consists in reacting a compound of general formula (IV), in which R1 is as defined in the general formula (I) and W represents a hydroxyl, mesylate or tosylate group or a chlorine, bromine or iodine atom, with an oxazolidinedione of general structure (V), in which R3 is as defined in the general formula (I), in order to provide the oxazolidinedione derivative of general structure (VI).
- In the case where W represents a hydroxyl group, the reaction can be carried out according to the Mitsunobu conditions (Synthesis, 1981, 1-28), for example by the action of diethyl or diisopropyl azodicarboxylate in the presence of triphenylphosphine. In the case where W represents a chlorine, bromine or iodine atom or a mesylate or tosylate group, the reaction can be carried out in the presence of a base, such as 1,1,3,3-tetramethylguanidine, sodium hydride or sodium tert-butoxide, in a solvent, such as tetrahydrofuran, acetonitrile or dimethylformamide, at a temperature between 0° C. and 80° C. The oxazolidinedione derivative of general formula (VI) thus obtained is subsequently converted to the compound of general formula (I) in which R2 represents a hydrogen atom by aminolysis using an amine of general formula R4NH2 where R4 is as defined in the general formula (I).
- The compounds of general formulae (II), (IV) and (V) and also the alcohols of general formula HOCHR3CONHR4 and the amines of general formula R4NH2, when their method of preparation is not described, are available commercially or are described in the literature or can be prepared according to various methods described in the literature or known to a person skilled in the art.
- The invention, according to another aspect of its aspects, also has as subject-matter the compounds of formula (VI). These compounds are of use as intermediates in the synthesis of the compounds of formula (I).
- The examples which follow illustrate the preparation of some compounds of the invention. These examples are not limiting and serve only to illustrate the invention. The microanalyses, the IR and NMR spectra and/or LC-MS (liquid chromatography coupled to mass spectroscopy) confirm the structures and the purities of the compounds obtained. M.p. (° C.) represents the melting point in degrees Celsius. The numbers shown between brackets in the titles of the examples correspond to those in the 1st column of the table below.
- A solution of 136 mg (0.65 mmol) of 2-(methylamino)-2-oxoethyl phenyl carbonate and of 133 mg (0.85 mmol) of decylamine in 2 ml of dichloromethane is stirred at ambient temperature for 18 h.
- The solvent is evaporated under reduced pressure and the evaporation residue is chromatographed on a column of silica gel, elution being carried out with a 2% mixture of methanol in dichloromethane.
- The product obtained is crystallized from diisopropyl ether to result in 135 mg of white solid.
- LC-MS: M+H=273
- M.p. (° C.): 98-100° C.
- 1H NMR (CDCl3)•(ppm): 6.10 (broad signal, 1H), 4.80 (broad signal, 1H), 4.60 (s, 2H), 3.20 (q, 2H), 2.85 (d, 3H), 1.65-1.45 (m, 4H), 1.45-1.20 (m, 12H), 1.00-0.80 (m, 3H).
- 420 mg (1.98 mmol) of (11Z)-tetradec-11-en-1-ol, in solution in 2 ml of tetrahydrofuran, are added to a solution of 200 mg (1.98 mmol) of 1,3-oxazolidine-2,4-dione and of 571 mg (2.18 mmol) of triphenylphosphine in 4 ml of tetrahydrofuran. 0.99 ml (2.2 mmol) of a 40% solution of diethyl azodicarboxylate in toluene is subsequently added dropwise. The mixture is stirred at ambient temperature for 5 h.
- The solvent is evaporated under reduced pressure and the evaporation residue is purified by chromatography on a column of silica gel, elution being carried out with a gradient of 10 to 50% of ethyl acetate in cyclohexane.
- 490 mg of a yellow oil are thus obtained.
- 1H NMR (CDCl3) δ (ppm): 5.25 (m, 2H), 4.60 (s, 2H), 3.45 (t, 2H), 2.10-1.80 (m, 4H), 1.65-1.45 (m, 2H), 1.40-1.05 (m, 14H), 0.90 (t, 3H).
- 6 ml of a 2M solution of methylamine in methanol are added to a solution of 240 mg (0.81 mmol) of 3-[(11Z)-tetradec-11-en-1-yl]-1,3-oxazolidine-2,4-dione, obtained in stage 2.1, in 1.5 ml of methanol.
- The mixture is stirred at ambient temperature for 2 h, then the solvent is evaporated under reduced pressure and the evaporation residue is purified by chromatography on a column of silica gel, elution being carried out with a gradient of 70 to 100% of ethyl acetate in cyclohexane.
- A yellow solid is isolated and is treated with ultrasound for 30 minutes in a mixture of 0.5 ml of ethyl acetate and of 4 ml of cyclohexane. The solid is separated by centrifuging and removing the supernatant.
- After drying, 74 mg of a pale yellow solid are thus obtained.
- LC-MS: M+H=327
- M.p. (° C.): 79-81° C.
- 1H NMR (d6-DMSO) δ (ppm): 7.75 (broad s, 1H), 7.15 (broad t, 1H), 5.30 (m, 2H), 4.30 (s, 2H), 2.95 (m, 2H), 1.60 (d, 3H), 1.95 (m, 4H), 1.40-1.15 (m, 16H), 0.90 (t, 3H).
- 6 ml of a 2M solution of ammonia in methanol are added to a solution of 240 mg (0.81 mmol) of 3-[(11Z)-tetradec-11-en-1-yl]-1,3-oxazolidine-2,4-dione, obtained in stage 2.1 of Example 2, in 1.5 ml of methanol.
- The mixture is stirred at ambient temperature for 18 h and then the solvent is evaporated under reduced pressure. The evaporation residue is chromatographed on a column of silica gel, elution being carried out with a gradient of 80 to 100% of ethyl acetate in cyclohexane.
- A yellow solid is isolated and is treated with ultrasound for 30 minutes in a mixture of 1 ml of ethyl acetate and of 4 ml of cyclohexane. The solid is separated by centrifuging and removing the supernatant.
- After drying, 99 mg of a pale yellow solid are thus obtained.
- LC-MS: M+Na=335
- M.p. (° C.): 120-123° C.
- 1H NMR (d6-DMSO) δ (ppm): 7.30-7.05 (m, 3H), 5.30 (m, 2H) 4.30 (s, 2H), 2.95 (m, 2H), 2.00 (m, 4H), 1.45-1.15 (m, 16H), 0.90 (t, 3H).
- The chemical structures and the physical properties of some compounds according to the invention are illustrated in the following Table 1.
- In this table:
-
- the “M.p. (° C.)” column teaches the melting points of the products in degrees Celsius. “N.D” means that the melting point is not determined.
- the “LC-MS or (MS)” column teaches the results of analysis of products by LC-MS (liquid chromatography coupled to mass spectroscopy), carried out on an Agilent LC-MSD Trap device in positive ESI mode, or by MS (mass spectroscopy), on an Autospec M device (EBE) using the DC1—NH3 technique.
-
TABLE 1 (I) M.p. LC-MS or No. R1 R2 R3 R4 (° C.) (MS) 1 Pent-1-yl H CH3 H 132-134 (M + H 203) 2 (2E)-Hex-2-en-1- H H CH3 85-87 M + Na 237 yl 3 (2E)-Hex-2-en-1- H H H 126-128 M + Na 223 yl 4 (2Z)-Hex-2-en-1- H H H 102-104 M + Na 223 yl 5 (3Z)-Hex-3-en-1- H H H N.D M + Na 223 yl 6 (3E)-Hex-3-en-1- H H H 138-140 M + Na 223 yl 7 (3Z)-Hex-3-en-1- H H CH3 72-74 M + Na 237 yl 8 (3E)-Hex-3-en-1- H H CH3 88-90 M + Na 237 yl 9 (2Z)-Hex-2-en-1- H H CH3 74-76 M + Na 237 yl 10 Hex-1-yl H H CH3 86-88 M + H 217 11 Hex-1-yl H CH3 H 123-125 (M + H 217) 12 Hex-1-yl Hex- H CH3 N.D M + H 301 1-yl 13 Hept-1-yl H H CH3 87-89 M + H 231 14 (2E)-Oct-2-en-1- H H CH3 80-82 M + Na 265 yl 15 (2E)-Oct-2-en-1- H H H 126-128 M + Na 251 yl 16 (3Z)-Oct-3-en-1- H H CH3 62-64 M + Na 265 yl 17 (3Z)-Oct-3-en-1- H H H 113-115 M + Na 251 yl 18 (5Z)-Oct-5-en-1- H H H 122-124 M + Na 251 yl 19 (5Z)-Oct-5-en-1- H H CH3 69-71 M + Na 265 yl 20 Oct-7-en-1-yl H H H 122-124 M + Na 251 21 Oct-7-en-1-yl H H CH3 72-74 M + Na 265 22 Cyclooct-1-yl H H CH3 81-83 M + H 243 23 Oct-1-yl H CH3 H 130-132 (M + H 245) 24 1-Methylhept-1-yl H H CH3 N.D M + H 267 25 Non-1-yl H H CH3 95-97 M + H 259 26 Dec-1-yl H H CH3 98-100 M + H 273 27 Dec-1-yl H CH3 H 133-135 (M + H 273) 28 1-Methyldec-1-yl H H CH3 71-73 M + H 287 29 Cyclododec-1-yl H H CH3 171-173 M + H 299 30 Dodec-1-yl H H CH3 103-105 M + H 301 31 (11Z)-Tetradec- H H H 120-123 M + Na 335 11-en-1-yl 32 (11Z)-Tetradec- H H CH3 79-81 M + H 327 11-en-1-yl 33 Tetradec-1-yl H H CH3 106-108 M + H 329 34 (9Z)-Hexadec-9- H H H 127-129 M + H 341 en-1-yl M + Na 363 35 (9Z)-Hexadec-9- H H CH3 69-71 M + H 355 en-1-yl M + Na 377 36 1-Methyltridecyl H H CH3 82-84 M + H 329 37 Pentadec-1-yl H H CH3 107-109 M + H 343 38 (6E, 9E, 12E)- H H CH3 N.D M + H 379 Octadeca-6,9,12- trien-1-yl 39 (6Z)-Octadec-6- H H H 100-102 M + H 369 en-1-yl M + Na 391 40 (6Z)-Octadec-6- H H CH3 72-74 M + H 383 en-1-yl 41 Octadec-1-yl CH3 H CH3 85-87 M + H 399 42 (4Z, 7Z, 10Z, 13Z)- H H H N.D M + H 377 Nonadeca- 4,7,10,13- tetraen-1-yl 43 Nonadec-1-yl H H CH3 113-115 M + H 399 44 (5Z, 8Z, 11Z, 14Z)- H H CH3 N.D M + H 405 Icosa-5,8,11,14- tetraen-1-yl 45 (11E, 14E, 17E)- H H CH3 57-59 M + H 407 Icosa-11,14,17- M + Na 429 trien-1-yl 46 (11E, 14E)-Icosa- H H CH3 58-60 M + H 409 11,14-dien-1-yl M + Na 431 47 (11E)-Icosa-11- H H CH3 77-79 M + H 411 en-1-yl M + Na 433 - The compounds of the invention have formed the subject of pharmacological trials which make it possible to determine their inhibitory effect on the enzyme FAAH (Fatty Acid Amido Hydrolase).
- The inhibitory activity was demonstrated in a radioenzymatic test based on the measurement of the product of hydrolysis ((1-3H)ethanolamine) of ((1-3H)ethanolamine)-anandamide by FAAH (Life Sciences (1995), 56, 1999-2005 and Journal of Pharmacology and Experimental Therapeutics (1997), 283, 729-734). Thus, mouse brains (minus the cerebellum) are removed and stored at −80° C. The membrane homogenates are prepared at the time of use by homogenization of the tissues with a Polytron in a 10 mM Tris-HCl buffer (pH 8) comprising 150 mM NaCl and 1 mM EDTA. The enzymatic reaction is subsequently carried out in 70 μl of buffer comprising bovine serum albumin free from fatty acids (1 mg/ml). The test compounds, at various concentrations, the ((1-3H)ethanolamine)-anandamide (specific activity of 15-20 Ci/mmol), diluted to 10 μM with non-radiolabelled anandamide, and the membrane preparation (400 μg of frozen tissue per assay) are successively added. After 15 minutes at 25° C., the enzymatic reaction is halted by addition of 140 μl of chloroform/methanol (2:1). The mixture is stirred for 10 minutes and is then centrifuged at 3500 g for 15 minutes. An aliquot (30 μl) of the aqueous phase comprising the (1-3H)ethanolamine is counted by liquid scintillation.
- Under these conditions, the most active compounds of the invention exhibit IC50 values (concentration which inhibits the control enzymatic activity of FAAH by 50%) of between 0.001 and 1 μM.
- For example, compounds Nos. 13, 22, 24 and 47 in the table respectively exhibit IC50 values of 0.091, 0.696, 0.089 and 0.154 μM respectively.
- It is therefore apparent that the compounds according to the invention have an inhibitory activity on the enzyme FAAH.
- The in viva activity of the compounds of the invention was evaluated in a test for analgesia.
- Thus, the intraperitoneal (i.p.) administration of PBQ (phenylbenzoquinone, 2 mg/kg in a 0.9% sodium chloride solution comprising 5% of ethanol) to male OF1 mice weighing 25 to 30 g causes abdominal tractions, on average 30 twisting or contracting motions during the period from 5 to 15 minutes after injection. The test compounds are administered, orally (p.o.) or intraperitoneally (i.p.) in suspension in 0.5% Tween 80, 60 minutes or 120 minutes before the administration of PBQ. Under these conditions, the most powerful compounds of the invention reduce by 35 to 70% the number of tractions induced by the PBQ, within a range of doses of between 1 and 30 mg/kg.
- The enzyme FAAH (Chemistry and Physics of Lipids, (2000), 108, 107-121) catalyses the hydrolysis of endogenous derivatives of amides and esters of various fatty acids, such as N-arachidonoylethanolamine (anandamide), N-palmitoylethanolamine, N-oleoylethanolamine, oleamide or 2-arachidonoylglycerol. These derivatives have various pharmacological activities by interacting, inter alia, with the cannabinoid and vanilloid receptors.
- The compounds of the invention block this decomposition pathway and increase the tissue level of these endogenous substances. They can therefore be used in the prevention and treatment of pathologies in which endogenous cannabinoids and/or any other substrate metabolized by the enzyme FAAH are involved.
- Mention may be made, for example, of the following diseases and conditions:
- pain, in particular acute or chronic pain of neurogenic type: migraine, neuropathic pain, including forms associated with the herpes virus and with diabetes; acute or chronic pain associated with inflammatory diseases: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome; acute or chronic peripheral pain; dizziness, vomiting, nausea, in particular resulting from chemotherapy; eating disorders, in particular anorexia and cachexia of various natures; neurological and psychiatric pathologies: tremors, dyskinesias, dystonias, spasticity, obsessive-compulsive behavior, Tourette's syndrome, all forms of depression and of anxiety of any nature and origin, mood disorders, psychoses; acute or chronic neurodegenerative diseases: Parkinson's disease, Alzheimer's disease, senile dementia, Huntington's chorea, lesions related to cerebral ischemia and to cranial and medullary trauma; epilepsy; sleep disorders, including sleep apnea; cardiovascular diseases, in particular hypertension, cardiac arrhythmias, arteriosclerosis, heart attack, cardiac ischemia; renal ischemia; cancers: benign skin tumors, brain tumors and papillomas, prostate tumors, cerebral tumors (glioblastomas, medulloepitheliomas, medulloblastomas, neuroblastomas, tumors of embryonic origin, astrocytomas, astroblastomas, ependymomas, oligodendrogliomas, plexus tumor, neuroepitheliomas, epiphyseal tumor, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, schwannomas); disorders of the immune system, in particular autoimmune diseases: psoriasis, lupus erythematosus, diseases of the connective tissue or collagen diseases, Sjögren's syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet's disease, autoimmune hemolytic anemia, multiple sclerosis, amyotrophic lateral sclerosis, amyloidosis, graft rejection, diseases affecting the plasmocytic line; allergic diseases: immediate or delayed hypersensitivity, allergic rhinitis or conjunctivitis, contact dermatitis; parasitic, viral or bacterial infectious diseases: AIDS, meningitis; inflammatory diseases, in particular joint diseases: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome; osteoporosis; eye conditions: ocular hypertension, glaucoma; pulmonary conditions: diseases of the respiratory tract, bronchospasm, coughing, asthma, chronic bronchitis, chronic obstruction of the respiratory tract, emphysema; gastrointestinal diseases: irritable bowel syndrome, inflammatory intestinal disorders, ulcers, diarrhea; urinary incontinence and bladder inflammation.
- The compounds of the invention can thus be used in the preparation of medicaments, in particular of medicaments which are inhibitors of the enzyme FAAH.
- Thus, according to another of its aspects, a subject-matter of the invention is medicaments which comprise a compound of formula (I) or a hydrate or a solvate of the compound of formula (I).
- These medicaments are used in therapeutics, in particular in the treatment and the prevention of the above-mentioned pathologies.
- According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention. These pharmaceutical compositions comprise an effective dose of at least one compound according to the invention or a hydrate or a solvate of the said compound and at least one pharmaceutically acceptable excipient.
- The said excipients are chosen, depending on the pharmaceutical form and the method of administration desired, from the usual excipients which are known to a person skilled in the art.
- In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intrathecal, intranasal, transdermal, pulmonary, ocular or rectal administration, the active principle of formula (I) above or its optional solvate or hydrate can be administered in a single-dose administration form, as a mixture with conventional pharmaceutical excipients, to animals and to man for the prophylaxis or the treatment of the above disorders or diseases.
- Appropriate single-dose administration forms comprise oral forms, such as tablets, soft or hard gelatin capsules, powders, granules, chewing gums and oral solutions or suspensions, forms for sublingual, buccal, intratracheal, intraocular or intranasal administration or for administration by inhalation, forms for subcutaneous, intramuscular or intravenous administration and forms for rectal or vaginal administration. For topical application, the compounds according to the invention can be used in creams, ointments or lotions.
- By way of example, a single-dose administration form of a compound according to the invention in the form of a tablet can comprise the following components:
-
Compound according to the invention 50.0 mg Mannitol 223.75 mg Croscarmellose sodium 6.0 mg Maize starch 15.0 mg Hydroxypropylmethylcellulose 2.25 mg Magnesium stearate 3.0 mg - The said single-dose forms comprise a dose which makes possible a daily administration of 0.1 to 20 mg of active principle per kg of body weight, depending upon the pharmaceutical dosage form.
- There may be specific cases where higher or lower dosages are appropriate; such dosages also come within the invention. According to the usual practice, the dosage appropriate to each patient is determined by the doctor according to the method of administration, the weight and the response of the said patient.
- According to another of its aspects, the invention also relates to a method for the treatment of the pathologies indicated above which comprises the administration of an effective dose of a compound according to the invention or of a solvate or of a hydrate of the said compound.
Claims (12)
1. A method of treating a disease in a patient, said disease selected from the group consisting of acute or chronic pain, dizziness, vomiting, nausea, eating disorder, neurological or psychiatric pathology, acute or chronic neurodegenerative disease, epilepsy, sleep disorder, cardiovascular disease, renal ischemia, disorders of the immune system, allergic disease, parasitic, viral or bacterial infectious disease, inflammatory disease, osteoporosis, gastrointestinal disease and urinary incontinence, comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a hydrate or a solvate thereof:
in which
R1 represents a C5-26-alkyl, C5-26-alkenyl or C5-26-alkynyl group or a polyunsaturated aliphatic carbon group comprising between 5 and 26 carbon atoms and comprising at least two unsaturations chosen from double and triple bonds;
R2 represents a hydrogen atom or a C1-6-alkyl group;
R3 represents a hydrogen atom or a C1-3-alkyl group; and
R4 represents a hydrogen atom or a C1-4-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkyl group.
2. The method according to claim 1 , wherein:
R1 represents a C5-26-alkyl group, a C5-26-alkenyl group or a polyunsaturated aliphatic carbon group comprising between 5 and 26 carbon atoms and comprising at least two unsaturations chosen from double bonds;
R2 represents a hydrogen atom or a C1-6-alkyl group;
R3 represents a hydrogen atom or a C1-3-alkyl group; and
represents a hydrogen atom or a C1-4-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkyl group.
3. The method according to claim 1 , wherein:
R3 represents a hydrogen atom or a C1-3-alkyl group; and
R4 represents a hydrogen atom or a C1-4-alkyl group.
4. The method according to claim 1 , wherein:
R1 represents a C10-20-alkyl, C10-20-alkenyl or C10-20-alkynyl group or a polyunsaturated aliphatic carbon group comprising between 10 and 20 carbon atoms and comprising at least two unsaturations chosen from double and triple bonds;
R2 represents a hydrogen atom or a C1-6-alkyl group;
R3 represents a hydrogen atom or a C1-3-alkyl group; and
R4 represents a hydrogen atom or a C1-4-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkyl group.
5. The method according to claim 1 , wherein:
R1 represents a C10-20-alkyl group, a C10-20-alkenyl group or a polyunsaturated aliphatic carbon group comprising between 10 and 20 carbon atoms and comprising at least two unsaturations chosen from double bonds;
R2 represents a hydrogen atom or a C10-20-alkyl group;
R3 represents a hydrogen atom or a C1-3-alkyl group; and
R4 represents a hydrogen atom or a C1-4-alkyl group.
6. The method according to claim 1 , wherein the disease is neurological or psychiatric pathology.
7. The method according to claim 6 , wherein said neurological or psychiatric pathology is selected from tremor, dyskinesia, dystonia, spasticity, obsessive-compulsive behavior, Tourette's syndrome, depression and anxiety.
8. The method according to claim 7 , wherein said neurological or psychiatric pathology is selected from depression or anxiety.
9. The method according to claim 1 , wherein the disease is acute or chronic neurodegenerative disease.
10. The method according to claim 9 , wherein said acute or chronic neurodegenerative disease is selected from Parkinson's disease, Alzheimer's disease, senile dementia, Huntington's chorea and lesions related to cerebral ischemia, cranial and medullary trauma.
11. The method according to claim 1 , wherein the disease is epilepsy.
12. The method according to claim 1 , wherein the disease is sleep disorder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/328,386 US20090088470A1 (en) | 2005-05-03 | 2008-12-04 | Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0504492 | 2005-05-03 | ||
FR0504492A FR2885364B1 (en) | 2005-05-03 | 2005-05-03 | ALKYL-, ALKENYL- AND ALKYNYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
PCT/FR2006/000958 WO2006117461A2 (en) | 2005-05-03 | 2006-04-28 | Alkyl-, alkenyl- et alkynyl carbamate derivatives, the preparation and therapeutic use thereof |
US11/874,959 US7476756B2 (en) | 2005-05-03 | 2007-10-19 | Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics |
US12/328,386 US20090088470A1 (en) | 2005-05-03 | 2008-12-04 | Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/874,959 Continuation US7476756B2 (en) | 2005-05-03 | 2007-10-19 | Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090088470A1 true US20090088470A1 (en) | 2009-04-02 |
Family
ID=35502576
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/874,959 Expired - Fee Related US7476756B2 (en) | 2005-05-03 | 2007-10-19 | Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics |
US12/328,386 Abandoned US20090088470A1 (en) | 2005-05-03 | 2008-12-04 | Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/874,959 Expired - Fee Related US7476756B2 (en) | 2005-05-03 | 2007-10-19 | Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics |
Country Status (11)
Country | Link |
---|---|
US (2) | US7476756B2 (en) |
EP (1) | EP1879856B1 (en) |
JP (1) | JP4857332B2 (en) |
AR (1) | AR056337A1 (en) |
AT (1) | ATE502006T1 (en) |
DE (1) | DE602006020713D1 (en) |
FR (1) | FR2885364B1 (en) |
MY (1) | MY144763A (en) |
TW (1) | TW200720235A (en) |
UY (1) | UY29518A1 (en) |
WO (1) | WO2006117461A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5448164B2 (en) | 2006-07-28 | 2014-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Compounds that modulate the CB2 receptor |
MX2009002888A (en) | 2006-09-25 | 2009-03-31 | Boehringer Ingelheim Int | Compounds which modulate the cb2 receptor. |
JP5492092B2 (en) | 2007-11-07 | 2014-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Compounds that modulate the CB2 receptor |
WO2009105509A1 (en) * | 2008-02-21 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the cb2 receptor |
US8178568B2 (en) | 2008-07-10 | 2012-05-15 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the CB2 receptor |
AU2009296838A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which selectively modulate the CB2 receptor |
FR2941696B1 (en) * | 2009-02-05 | 2011-04-15 | Sanofi Aventis | AZASPIRANYL-ALKYLCARBAMATES DERIVATIVES OF 5-CHAIN HETEROCYCLES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
EP2443107B1 (en) | 2009-06-16 | 2018-08-08 | Boehringer Ingelheim International GmbH | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
JP2013505295A (en) | 2009-09-22 | 2013-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Compound that selectively modulates CB2 receptor |
US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
JP5746228B2 (en) | 2010-03-05 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tetrazole compound that selectively modulates CB2 receptor |
US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
JP5746764B2 (en) | 2010-07-22 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Compounds that modulate the CB2 receptor |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3915755A1 (en) * | 1989-05-13 | 1990-11-29 | Bayer Ag | FUNGICIDAL AGENTS AND SUBSTITUTED AMINO ACID DERIVATIVES AND THE PRODUCTION THEREOF |
DE19533219A1 (en) * | 1995-09-08 | 1997-03-13 | Basf Ag | Process for the preparation of N-alkenylcarbamic acid esters |
AU1969201A (en) * | 1999-10-18 | 2001-04-30 | University Of Connecticut, The | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
FR2843964B1 (en) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | DIOXANE-2-ALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
FR2854633B1 (en) * | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | PIPERIDINYL-AND PIPERAZINYL-ALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2860514A1 (en) * | 2003-10-03 | 2005-04-08 | Sanofi Synthelabo | ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
-
2005
- 2005-05-03 FR FR0504492A patent/FR2885364B1/en not_active Expired - Fee Related
-
2006
- 2006-04-28 DE DE602006020713T patent/DE602006020713D1/en active Active
- 2006-04-28 WO PCT/FR2006/000958 patent/WO2006117461A2/en not_active Application Discontinuation
- 2006-04-28 AT AT06755462T patent/ATE502006T1/en not_active IP Right Cessation
- 2006-04-28 MY MYPI20061993A patent/MY144763A/en unknown
- 2006-04-28 EP EP06755462A patent/EP1879856B1/en active Active
- 2006-04-28 JP JP2008509467A patent/JP4857332B2/en not_active Expired - Fee Related
- 2006-05-02 AR ARP060101764A patent/AR056337A1/en unknown
- 2006-05-03 UY UY29518A patent/UY29518A1/en unknown
- 2006-05-03 TW TW095115753A patent/TW200720235A/en unknown
-
2007
- 2007-10-19 US US11/874,959 patent/US7476756B2/en not_active Expired - Fee Related
-
2008
- 2008-12-04 US US12/328,386 patent/US20090088470A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MY144763A (en) | 2011-10-31 |
FR2885364B1 (en) | 2007-06-29 |
AR056337A1 (en) | 2007-10-03 |
DE602006020713D1 (en) | 2011-04-28 |
TW200720235A (en) | 2007-06-01 |
WO2006117461A3 (en) | 2006-12-28 |
US7476756B2 (en) | 2009-01-13 |
WO2006117461A2 (en) | 2006-11-09 |
US20080103197A1 (en) | 2008-05-01 |
EP1879856A2 (en) | 2008-01-23 |
UY29518A1 (en) | 2006-11-30 |
EP1879856B1 (en) | 2011-03-16 |
ATE502006T1 (en) | 2011-04-15 |
JP4857332B2 (en) | 2012-01-18 |
JP2008540388A (en) | 2008-11-20 |
FR2885364A1 (en) | 2006-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7476756B2 (en) | Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics | |
US7777057B2 (en) | Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | |
US7482346B2 (en) | Derivatives of alkylpiperazine and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors | |
US8026258B2 (en) | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | |
EP1720872B1 (en) | Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors | |
EP1720550B1 (en) | Derivatives of piperidinylalkylcarbamates, preparation method thereof and use of same as faah enzyme inhibitors | |
US20110237595A1 (en) | Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |